Sexual Dysfunction

One only needs to do a Google search for “testosterone clinic” to realize there’s an explosion of for-profit businesses branded as men’s health establishments, offering what sounds like the fountain of youth to men with “low T” and sexual dysfunction. Unless one of these practices is affiliated with an academic medical center or urology group, there’s a good chance urologists are not part of the picture.

Also look for coverage of products in the pipeline for bladder pain syndrome/interstitial cystitis, prostate cancer, and male infertility.

Peyronie’s disease (PD) is surgically treated by a minority of urologists, and urologists who subspecialize in andrology perform a disproportionate number of procedures to treat the condition. Those were among the findings of a case-log analysis that was presented at the 2015 AUA annual meeting in New Orleans and subsequently published in Urology (2016; 87:205-9).

Results from a recently published set of coordinated trials indicate that raising testosterone concentrations offers moderate benefits in sexual function and some benefit on mood and depressive symptoms.

Check out the latest new products. From Single-use ureteroscope addresses shortcomings of reusable scopes, to an App that helps IC, chronic prostatitis patients choose the right foods and much more.

The future of erectile dysfunction management following prostate cancer surgery will likely include novel options, among them cell-based therapies, North American experts in the field predict.

Other pipeline products discussed in this article include an immunotherapy for metastatic bladder cancer, a treatment for lower urinary tract symptoms of BPH, and an investigational clear cell renal cell carcinoma treatment.

In this article, we review the etiology and pathophysiology of ED in this challenging patient population and provide an approach to treatment and risk reduction via lifestyle modification and pharmacologic intervention.

Learn more about these products as well as a powered exam table and an app that measures, monitors, and helps improve fertility in men.

Other pipeline products discussed in this article include agents for urinary catheter blockage, prostate cancer, bladder cancer, and overactive bladder.

The recently published AUA practice guideline on Peyronie’s disease provides current clinical principles on diagnosis and treatment of a highly prevalent and clinically significant condition, according to the co-chair of the multidisciplinary panel that developed the guideline.

Other products highlighted in this slideshow include a trial system for incontinence therapy, a compact catheter, a wearable digital technology solution for continence care assessment and management, and laser fiber and sheath system.

A prostate cancer vaccine and an infertility diagnostic tool are among the other pipeline products discussed in this round-up.

Shock wave therapy has now been subjected to multiple randomized, placebo-controlled, and additional open-label studies in clinics worldwide, demonstrating impressive efficacy and safety.

Experience with low-intensity extracorporeal shock wave therapy from multinational clinical trials demonstrates it is a safe, effective, and well-tolerated treatment for erectile dysfunction, including in men who do not respond to an oral phosphodiesterase type-5 inhibitor, reported Robert Feldman, MD, at the AUA annual meeting in New Orleans.

The association between testosterone replacement therapy (TRT) and thrombotic risk in elderly men remains controversial. While the FDA has mandated that all approved testosterone products include warnings about a possible increase in cardiovascular, stroke, and venous blood clot risk, at least one study presented at the AUA annual meeting in New Orleans found no link between TRT and cardiovascular events.

In this round-up of new urology products and services, learn about the FDA approving an oral agent for HSDD, an app that helps men with erectile dysfunction, and more.

In this installment of "Product Preview," also look for information on products in the pipeline for renal cell carcinoma and interstitial cystitis.

Here are the AUA 2015 take-home messages on sexual/dysfunction, presented by Landon Trost, MD.

Two recently published studies significantly contribute to current knowledge regarding testosterone therapy and cardiovascular health, says one expert urologist.

In this round-up of new urology products and services, learn about an app that helps moviegoers with OAB, a new mesh for sacrocolpopexy, and device/smartphone app that help women with pelvic floor exercises.

A novel investigational oral testosterone replacement therapy restored and maintained testosterone levels to a eugonadal range in 88% of hypogondal men treated with the agent in a randomized clinical trial.

Use of testosterone replacement therapy more than tripled between 2003 and 2012 in a population of reproductive-age men, according to a study presented at the AUA annual meeting in New Orleans.

“The FDA is being very cautious, which as the protector of public health, it’s got to be," says one urologist.

Urology Times’ “Best of AUA 2015” report provides a guide to the meeting’s take-home messages in 15 therapeutic areas-an information-packed, condensed summary of the top papers and presentations.

A study of more than 300 men sheds new light on the prostate safety of testosterone replacement therapy.

Other products featured include: Radiosurgery collimator allows treatment of broad rang of tumors and Phi prostate cancer test and more.

Most health information seekers navigate the Internet for what they think will be the best information available about their health condition or that of a loved one. Unfortunately, the Internet is unfiltered, unregulated, and often saturated with promotional, unsubstantiated, and at times frightening information.

Patients taking to the Internet for information about testosterone replacement therapy are likely getting an incomplete picture of the potential risks and adverse effects linked with the treatment, say researchers from Northwestern University Feinberg School of Medicine, Chicago, and the University of Pennsylvania, Philadelphia.

Products in the pipeline for prostate cancer, bladder cancer, and much more.